Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 701–800 of 1,871
Moreno, Ó., Reyes‐García, R., Guillen-Morote, C., Doulatram‐Gamgaram, V. K., Cases, C. C., Mendoza, N. A., Pérez, C. T., Cárdenas‐Salas, J., Martínez‐Fuster, S., Lardiés‐Sánchez, B., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf227 · Cited by 8
Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide
Verma, S., Cosentino, F., & Kosiborod, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae744 · Cited by 3
Stop Sitting on Our RAASes: Get Moving with the Most Effective Care for Our Patients
Lafayette, R. A. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000473 · Cited by 4
Late-life semaglutide treatment slows ageing and extends lifespan in female mice
Feng, Y., Barthez, M., Wang, Y., Chen, Y., Qiu, H., Wang, C.-L., Heydari, K., Delcroix, M., Rasmussen, L. J., Bohr, V. A., et al. (2026) · Nature · doi:10.1038/s41586-026-10940-7 · Cited by 9
Diallo, A., Carlos‐Bolumbu, M., Duc, P., & Galtier, F. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103506 · Cited by 4
“…of confidence in the network meta-analysis were considered: reporting bias, indirectness, imprecision, heterogeneity, incoherence, and within-study bias which was assessed using the Cochrane Collaboration’s revised Risk of Bias Tool (Rob2), 20 with more details are provided in Appendix (pages 6–8).”
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Self-citationMedical Therapy versus Bariatric Surgery in Kidney Transplant Candidates
Bzoma, B., Iqbal, A., Diwan, T. S., & Kukla, A. (2025) · Kidney360 · doi:10.34067/kid.0000000813 · Cited by 4
Pedicino, D., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae429 · Cited by 3
Rico-Fontalvo, J. E., Daza-Arnedo, R., Elbert, A. E., Correa‐Rotter, R., Diná-Batlle, E., Lorca, E., de Moraes, T. P., Sánchez-Polo, V., & Builes-Montaño, C. E. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01854-8 · Cited by 6
“These observations align closely with the antiproteinuric and eGFR‑sta‑ bilizing effects observed in FLOW and SELECT [13, 18].”
InfluentialTangri, N., Ferguson, T. W., Teng, C., Bamforth, R. J., Smith, J. L., Guzman, M., & Goss, A. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000817 · Cited by 13
Triple Agonist Therapy: A New Frontier in Treating Type 2 Diabetes and Obesity
Whitley, H. P. (2025) · Clinical Diabetes · doi:10.2337/cd25-0018 · Cited by 3
Karalliedde, J. J., McCafferty, K., Winocour, P. H., Chowdhury, T. A., Kanumilli, N., De, P., Frankel, A., Doherty, C., Milne, N., Montero, R., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.07.028 · Cited by 4
“29,30 Currently, there is 1 primary kidney end point study reported with this class of agent in 3533 participants with T2DM and CKD where the Effects of Semaglutide on CKD in Patients with Type 2 Diabetes trial (FLOW) 12 was evaluated.”
Omer, K., Clemens, K. K., Zhu, Y., Lapier, H., MOIST, L. M., Ernst, J., Reichert, S. M., Iansavitchene, A., & Chiu, M. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101004 · Cited by 3
“13 There were no specified dietary or exercise suggestions for participants or any described coaching or multidisciplinary involvement.”
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial
Guo, L., Sun, Z., Zhang, L., Qin, G., Li, Y., Chen, X., Xu, N., Su, X., Li, M. T., Sun, J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.15622 · Cited by 5
Optimal patient care in advanced chronic kidney disease progressing to kidney failure
Combe, C., de Pinho, N. A., Guedes, M. H., Frimat, L., Fouque, D. P., Liabeuf, S., Niang, A., Kanjanabuch, T., Stengel, B., Massy, Z. A., et al. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01056-2 · Cited by 10
GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Ramadurgum, P., Sharma, K. M., Pinon, A., Kattamuri, L. P. V., & Botros, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02356-6 · Cited by 3
Narula, J., Butler, J., Chothia, M., Bannerjee, D., Jarraya, F., Ulasi, I., & Luyckx, V. A. (2025) · African Journal of Nephrology · doi:10.21804/28-1-7360 · Cited by 3
Association of pancreas fat fraction with adverse kidney and cardiovascular outcomes
Thomas, P., Salud, M. I., Missikpode, C., Martinez, O. G., Verma, A., Zhao, R., Claudel, S. E., Schmidt, I. M., van Raalte, D. H., Bjornstad, P., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf310 · Cited by 4
Choudhury, I., Ward, J. H., Mahesh, S., Alam, U., Azmi, S., & Anson, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.02.010 · Cited by 5
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
Graham, T., Raghinaru, D., Afreen, S., Ahmann, A., Haidar, A., Raskin, P., Tsoukas, M., Lum, J., Sasson-Katchalski, R., Pinsker, J. E., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1753 · Cited by 3
Seven unanswered questions about blockbuster weight-loss drugs
May, M. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03380-1 · Cited by 3
GLP-1 Receptor Agonists Help Legs
Goldenberg, R., & Verma, S. (2025) · Diabetes Care · doi:10.2337/dci25-0070 · Cited by 6
Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis
Klein, K. R., Menacher, A., Buse, J. B., Mann, J. F. E., Tuttle, K. R., Kvist, K., Andersen, M. R., Mayrdorfer, M., & Lingvay, I. (2026) · Diabetes Care · doi:10.2337/dc26-0112 · Cited by 3
Self-citationKrólewski, A. S., Haukka, J. K., Dom, Z. I. M., Curovic, V. R., Wu, C., Morieri, M. L., Ihara, K., Tye, S. C., Kobayashi, H. H., Keum, Y., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000863 · Cited by 7
Self-citationKaracabeyli, D., & Lacaille, D. V. (2026) · Rheumatology · doi:10.1093/rheumatology/keag147 · Cited by 4
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Optimizing care for chronic kidney disease: Considerations from A to Z
Chen, F.-Y., Chang, W., Kao, Z.-K., Tan, A. C., Li, S., Yang, C.-Y., Lin, H., & Lin, C.-C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001280 · Cited by 7
Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes
Cai, C. X., Toy, B. C., Martin, B., Ruochong, F. A. N., Westlund, E., Tran, D., Nishimura, A., Lee, H., Leng, T., Nagy, P. G., et al. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.05.034 · Cited by 6
Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes
Parveen, S., Malmborg, M. W., Arulmurugananthavadivel, A., Carlson, N., Andersson, C., Andersen, C. F., Jensen, J., Zahir, D., Elmegaard, M., Eroglu, T. E., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102254 · Cited by 9
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 8
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
Valério, C. M., Saraiva, J. F. K., Valente, F., van de Sande‐Lee, S., Rocha, V. Z., Rached, F. H., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01954-8 · Cited by 11
“…in CV death risk (HR 0.71; 95% CI: 0.56–0.89), 21% reduction in composite renal outcomes (HR 0.79; 95% CI: 0.66–0.94), 18% reduction in the risk of severe CV events (HR 0.82; 95% CI: 0.68–0.98; p = 0.029), and a 20% reduction in all-cause mortality (HR 0.80; 95% CI: 0,67–0,95; p = 0,01) [65].”
InfluentialEconomos, H., & MacIsaac, R. J. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i4.109457 · Cited by 5
Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity
Innocent, B., Elmaoued, A. A., Cowart, K., & White, R. T. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf088 · Cited by 5
van Baar, M. J. B., Muskiet, M. H. A., Scholtes, R. A., Touw, D. J., Nieuwdorp, M., Kramer, M. H. H., Joles, J. A., Cherney, D. Z. I., Bjornstad, P., Krebber, M. M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16431 · Cited by 3
“16 Previous kidney mechanistic T2D studies show that DPP-4 inhibition has no effect on fasting kidney haemodynamics: sitagliptin did not affect kidney haemody-namics 17 or only modestly reduced fasting P GLO compared to placebo, 18 whereas linagliptin also had no effect compared to SU-derivative…”
Zac‐Varghese, S. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100512 · Cited by 5
Rayner, B. L., Mahaffey, K. W., Mann, J. F. E., Pratley, R. E., Rossing, P. R., Belmar, N., Bosch‐Traberg, H., Jeppesen, O. K., Tran, M. C., Chernin, G., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag036 · Cited by 5
“…Renal Function with Semaglutide Once-Weekly) phase 3 clinical trial (NCT03819153), treatment with once-weekly subcutaneous semaglutide 1.0 mg, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), reduced risks of major kidney, CV and mortality outcomes in participants with T2D and CKD [ 18 ].”
InfluentialSelf-citationGlobal kidney health: Are we failing the silent pandemic?
Yi, T. W., O’Hara, D. V., & Levin, A. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70088 · Cited by 5
“Several new therapies have been established as disease-modifying therapies for cardiorenal protection, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i) [76–78], nonsteroidal mineralo-corticoid receptor antagonists [79], and glucagon-like peptide-1 receptor agonists [80].”
Sunagawa, K., Hirai, K., Sunagawa, S., Kamiya, N., Komesu, I., Sunagawa, Y., Sunagawa, H., Nakachi, K., Hirai, A., Ookawara, S., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s471535 · Cited by 4
“26 These trials demonstrated that GLP-1 analogs reduced composite renal events including ≥ 30–50% reduction in eGFR and initiation of renal replacement therapy by 15–35%.”
BackgroundBrook, D., & SINGER, P. A. (2024) · medRxiv · doi:10.1101/2024.11.11.24317112 · Cited by 3
Garagoli, F., Masson, W. M., Barbagelata, L., & Lobo, M. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endinu.2025.501562 · Cited by 14
Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-06245-w · Cited by 8
Trillini, M., Jenssen, T. G., Martin, W. P., & Morales, E. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf008 · Cited by 5
The important role of comorbidities in the management of obesity
Barenbaum, S. R., Tchang, B. G., & Aronne, L. J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag012 · Cited by 5
Management of Diabetes in Patients with Chronic Kidney Disease
Ambalavanan, J., & Caramori, M. L. (2025) · Endocrine Research · doi:10.1080/07435800.2025.2473896 · Cited by 5
Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment
Zoccali, C., Caterina, R. D., Tuttle, K. R., Burnier, M., Massy, Z. A., Mallamaci, F., Ferro, C. J., & Zannad, F. M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag220 · Cited by 5
Self-citationAgarwal, R., Nangaku, M., Chen, L., Wang, A. Y.-M., Yanagita, M., Bavanandan, S., Satirapoj, B., Prasad, N., Lim, S. K., Sriwijitkamol, A., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000909 · Cited by 6
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Georgianos, P. I., Leivaditis, K., & Liakopoulos, V. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14284 · Cited by 3
“8,9”
Efficacy and Safety of Oral Semaglutide in Managing Type 2 Diabetes in India: A Real-World Study
Ray, S., Ray, A., Goutam, S., & Mitra, A. (2024) · Clinical Diabetology · doi:10.5603/cd.102374 · Cited by 5
Kędzierska-Kapuza, K., Grudniewska, A., Durma, A. C., Małecki, R., Franek, E., & Szczuko, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134701 · Cited by 5
Cardiovascular-kidney-metabolic syndrome and treatment advances: a narrative review
Peña, C., Flores, J., & NUGENT, K. M. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09607-7 · Cited by 6
Reframing the Role of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Medicine
Inciardi, R. M., Chandra, A., Pandey, A., & Metra, M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15123 · Cited by 4
The FLOW of Progress in Diabetic Kidney Disease: Semaglutide’s Role in Combination Therapy
Agarwal, R. (2025) · Diabetes Care · doi:10.2337/dci25-0088 · Cited by 6
Abdullah, A., Sagreeka, F. N. U., Aniket, G. A., Lal, R., Geeta, F. N. U., Bai, A., Ahmed, G. U., Raza, A. A., Shaikh, V. F., Sanaullah, O., et al. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70136 · Cited by 3
“Reduction in major kidney adverse events was also, similarly, found in the study by Ashraf et al. and other studies [10, 11].”
InfluentialOganesova, Z., MacLaughlin, H. L., McCafferty, K., Potthoff, S., Greenwood, S. A., Vickerstaff, V., Batterham, R. L., Afuwape, S. A., Motallebzadeh, R., & Brown, A. C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103649 · Cited by 4
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Izumida, T., & Kinugawa, K. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0004 · Cited by 3
“48) Semaglutide reduced renal specific events by 21%, accompanied by only a modest initial decline in eGFR, suggesting its potential to preserve renal function without significant adverse effects.”
Marinho, L. L., Ribeiro, M. L., Lawler, P. R., Iatan, I., Godoy, L. C., Rached, F. H., & Maranhão, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01292-0 · Cited by 3
“The recent FLOW trial [94 ] showed 24% reduction in the risk of major kidney adverse outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease treated with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.”
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
Nalbandian, M., Lone, J. B., Moal, E. L., Kim, I., Jeuris, K., Li, Y. K., Kraft, P. E., Zhao, M., Koleckar, K., Zhang, Z., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2606533123 · Cited by 10
Yang, T., Xue, Y., Ren, J., Li, X., Xu, W., Nie, G., Wang, D., & Wang, X. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128390373250507062606 · Cited by 3
Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?
Weir, M. R. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151688 · Cited by 4
Eckel, R. H., Krentz, A. J., Jacob, S., & Libby, P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70033 · Cited by 3
“15 Exploiting the changing opportunities for improved care for cardio-renal-metabolic disease requires a coordinated multidisciplinary approach.”
The promise and hope of GLP-1 receptor agonists
Sumithran, P., & Ard, J. D. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00315-2 · Cited by 4
Kramer, H. J., & Bakris, G. L. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70066 · Cited by 4
“Use of a GLP-1 RA with proven CKD and CVD beneficial effects, such as semaglutide, may reduce symptoms and improve physical functioning in patients with obesity and HFpEF [118, 134, 135].”
InfluentialSelf-citationCan GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?
Ali, H., Alahmad, B., & Al‐Mulla, F. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04217-w · Cited by 3
“The trial showed that Semaglutide was associated with 24% reduction in major kidney disease events and a slower annual eGFR decline by 1.16 mL/min/1.73 m²/year compared to placebo in patients with DKD [5].”
InfluentialMorris, J., Battistella, M., Tennankore, K., Soroka, S., Kendell, C., Poyah, P. S., More, K. M., Grandy, M., Ransom, T. P. P., Kennie‐Kaulbach, N., et al. (2025) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241309974 · Cited by 4
Chen, J., Fang, Y., Liu, Y., Chen, M., & Tsai, M. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70187 · Cited by 6
Halimi, J., Fauchier, L., Karras, A., Amouyal, C., Eladari, D., Rossignol, P., Choukroun, G. J., Zaoui, P., Girerd, N., & Hadjadj, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf426 · Cited by 9
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial
Hofherr, A., Maki-Petaja, K. M., Selvarajah, V., Grice, D., Bartesaghi, S., Jiménez, E., Pecoits‐Filho, R., & Heerspink, H. J. L. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000966 · Cited by 6
Pham, H. N., Ibrahim, R., Abdelnabi, M. H., Bcharah, G., Mahmoud, A., Allam, M., Farina, J., Lee, J. Z., Singh, A., Ayoub, C., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf135 · Cited by 6
Management of the kidney transplant candidate with obesity
Abbasi, A. B., & Orandi, B. J. (2026) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001266 · Cited by 3
Chen, Q., Li, Y., Yang, S., He, H., Xie, Y., Wang, W., Wang, L., Gao, Y., Cai, L., Xiong, S., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38389 · Cited by 5
“In high-risk populations, targeted use of cardiorenal protective agents—including finerenone [34], glucagon-like peptide-1 (GLP-1) receptor agonists [35], and sodium-glucose cotransporter-2 (SGLT-2) inhibitors [36]—may attenuate the progression of atherosclerosis [14, 37].”
Longley, R. M., Katzenstein, C., & Mohottige, D. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02274-z · Cited by 4
“In the CURE-CKD registry of patients with T2DM and CKD, 6.8% of patients received GLP-1RAs at baseline [33], despite trials such as FLOW [36].”
InfluentialKhan, S. S., Bhave, N. M., Blumenthal, R. S., Coresh, J., Huang, X., Joseph, J. J., Khera, A., Ho, J. E., Lloyd‐Jones, D. M., Wang, C. C. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001447 · Cited by 19
GLP-1 receptor agonists—another promising therapy for Alport syndrome?
Boeckhaus, J., Mabillard, H. R., & Sayer, J. A. (2025) · Journal of Rare Diseases · doi:10.1007/s44162-024-00065-8 · Cited by 4
“While patients with semaglutide treatment had a slower eGFR decline ( − 2.19 vs. − 3.36 ml/min/m 2 per year), it led to more frequent discontinuation mainly due to gastrointestinal side effects [28].”
InfluentialLuna, E., Álvarez, Á., Sabillón, J. A. R., Villa, J., Giraldo, T., Martín, M. V. M., Vázquez, E., Fernández, N., Ruíz, B., García‐Pino, G., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070943 · Cited by 5
“Recently, the FLOW trial demonstrated a nephroprotective effect of semaglutide in patients with CKD and type 2 diabetes, as the risk of a primary outcome event was 24% lower, and the mean annual eGFR slope was less steep in the semaglutide group [27].”
InfluentialInceu, G. V., Crăciun, A.-E., Ciobanu, D. M., Berchisan, A., Fodor, A., Bala, C., Roman, G., & Rusu, A. (2025) · Medicina · doi:10.3390/medicina61081343 · Cited by 3
“Also, the presence of existing chronic kidney disease and cardiovascular disease may influence the choice of GLP-1 RAs over other drug classes due to their additional renal and cardiovascular benefits [28,30].”
Giugliano, D., Longo, M., Martino, N. D., Scappaticcio, L., Caruso, P., Bellastella, G., Maiorino, M. I., & Esposito, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70454 · Cited by 9
Tanaka, M., & Itoh, H. (2025) · International Summit on Diabetes, Endocrinology and Metabolic Disorders · doi:10.1038/s41440-025-02418-2 · Cited by 3
“Recently, renoprotective effect of semaglutide in individuals with type 2 DM and chronic kidney disease was reported [57].”
Elangovan, H., Loomba, R. S., Muthiah, M. D., Schattenberg, J. M., Zheng, M., Noureddin, M., Mantzoros, C. S., & George, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0857 · Cited by 5
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone
Agarwal, R., Correa‐Rotter, R., Navaneethan, S. D., Fukami, K., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001071 · Cited by 4
Self-citationRegistro Español de Diálisis y Trasplante (REDYT): informe del año 2023 y análisis evolutivo
Quiroga, B., Mahíllo, B., Mazuecos, A., Ortiz, A., Troya, M. I., Hernández-Marrero, D., Alemán, S. T., Santiuste, C., Arévalo, O. L. R., Marqués-Vidas, M., et al. (2026) · Nefrología · doi:10.1016/j.nefro.2026.501510 · Cited by 4
Beyond Glycemic Control: GLP-1RA–Based Therapies and Emerging Targets Beyond the Metabolic Axis
Matuszewski, W., Wołos-Kłosowicz, K., Włodarczyk, P., Waśniewska, P., Modzelewski, R., Górny, J. M., Szklarz, M., Madeksza, M., & Juranek, J. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072786 · Cited by 5
Yang, X., Tang, W., Chan, H., Wang, M., Yang, H., & Li, Q. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70144 · Cited by 4
“7,43 50 Ongoing trials are exploring extended indications, combination therapies and biomarkers to optimise personalised treatment.”
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
“22 Among GLP-1RAs, semaglutide can reduce CKD progression in patients with type 2 diabetes, 9 21 while its impact (as well as that of other GLP-1RAs) on the cardiorenal outcome of patients without diabetes remains to be confirmed.”
Birindwa, G., Mæng, M., Thrane, P. G., Gyldenkerne, C., Thomsen, R. W., & Olesen, K. K. W. (2024) · Clinical Epidemiology · doi:10.2147/clep.s463363 · Cited by 4
Circulating and Urinary CCL20 in Human Kidney Disease
Molina-Cazallas, N., García-Ayuso, D., Fernández‐Fernández, B., Rodríguez-Osorio, L., Sánchez-Rodríguez, J. E., Pérez-Gómez, M. V., Ortíz, A., & Ramos, A. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110563 · Cited by 2
Zhu, D., & Herrington, W. G. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-02459-jc · Cited by 2
Levi, J., Cross, S. H., Ramesh, N., et al. (2026) · medRxiv · doi:10.64898/2026.03.04.26347508 · Cited by 3
Infante, M., Ricordi, C., Pacifici, F., Pastore, D., Infante, R., Caprio, M., Chiereghin, F., Stefano, A. D., Frank, G., Rose, A. D., et al. (2026) · Nutrients · doi:10.3390/nu18132038 · Cited by 3
“Furthermore, incretin receptor agonists have been shown to confer cardiore-nal protection [6–9] and to exert significant beneficial effects in patients with metabolic dysfunction-associated steatohepatitis (MASH) and obstructive sleep apnea (OSA) [10,11].”
Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom
Ko, S., Domínguez, L., Ottaway, Z. V., Campbell, L. J., Fox, J. M., Burns, F. M., Hamzah, L., Ustianowski, A., Clarke, A. E., Kegg, S., et al. (2024) · HIV Medicine · doi:10.1111/hiv.13706 · Cited by 1
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
Raja, A., Qammar, A., Kumar, S., et al. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001828 · Cited by 2
Friedman, A. N., Oultache, I., & Hovey, R. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.03.037 · Cited by 3
Therapeutic Considerations in Preventing Chronic Kidney Disease
Nicholas, S. B., Nobakht, N., & Alicic, R. Z. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-013325 · Cited by 2
Shang, R., & Rodrigues, B. B. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf006 · Cited by 2
Buse, J. B., Christensen, H. N., Harty, B. J., Cziraky, M. J., Willey, V. J., & Skibsted, S. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005161 · Cited by 6
Plasma Interleukin 22 Predicts Progression of Early Diabetic Kidney Disease
Fernández‐Fernández, B., Hasegawa, T., Saruta, Y., Guan, Y. L., Sanz, A. B., Sánchez-Niño, M. D., Ramos, A. M., Sánchez-Rodríguez, J. E., Navarro‐González, J. F., & Ortíz, A. (2025) · American Journal of Nephrology · doi:10.1159/000547738 · Cited by 2
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.